ArticleExperimental biology and medicine (Maywood, N.J.)2021
12 Survival-related differentially expressed genes based on the TARGET-osteosarcoma database.
Article in Experimental biology and medicine (Maywood, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- The miR-16-1-3p passenger strand exhibits functional activity and suppresses malignant phenotypes in osteosarcoma.Frontiers in genetics · 2026Article
- WGCNA-identified COL13A1 drives osteosarcoma metastasis and progression via TGF-β signaling.Journal of bone oncology · 2025Article
- A multi-type programmed cell death gene signature predicts survival and reveals therapeutic targets in osteosarcoma.Discover oncology · 2025Article
- Identification of MAEA protein as a potential target for chemoresistance in osteosarcoma using bioinformatics and proteomic analysis.Frontiers in oncology · 2025Article
- Bayesian unsupervised clustering identifies clinically relevant osteosarcoma subtypes.Briefings in bioinformatics · 2024Article
- Comprehensive bioinformatics analysis and cell line experiments revealed the important role of CDCA3 in sarcoma.Heliyon · 2024Article
- Advances in prognostic models for osteosarcoma risk.Heliyon · 2024Review
- Osteosarcoma-Associated Immune Genes as Potential Immunotherapy and Prognosis Biomarkers.Biochemical genetics · 2024Article
- Review
- Comprehensive Analysis Reveals Prognostic and Therapeutic Immunity-Related Biomarkers for Pediatric Metastatic Osteosarcoma.Medicina (Kaunas, Lithuania) · 2024Article
- New insights into the mechanisms of the immune microenvironment and immunotherapy in osteosarcoma.Frontiers in immunology · 2024Review
- Proteomic and transcriptomic analyses identify apo-transcobalamin-II as a biomarker of overall survival in osteosarcoma.Frontiers in oncology · 2024Article
- High expression of integrin-binding sialoprotein (IBSP) is associated with poor prognosis of osteosarcoma.Aging · 2023Article
- Article
- Clinical significance and immune landscape of a novel ferroptosis-related prognosis signature in osteosarcoma.BMC cancer · 2023Article
- RNA-seq and Single-Cell Transcriptome Analyses of TRAIL Receptors Gene Expression in Human Osteosarcoma Cells and Tissues.Cancer informatics · 2023Article
- A Rab-bit hole: Rab40 GTPases as new regulators of the actin cytoskeleton and cell migration.Frontiers in cell and developmental biology · 2023Review
- Ubiquitin specific peptidase 11 as a novel therapeutic target for cancer management.Cell death discovery · 2022Review
- Single-cell RNA-seq identification of four differentially expressed survival-related genes by a TARGET: Osteosarcoma database analysis.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Developing a 5-Gene Signature Related to Pyroptosis for Osteosarcoma Patients.Journal of oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Therapeutically Applicable Research to Generate Effective Treatments (TARGET) project aims to determine molecular changes that drive childhood cancers, including osteosarcoma. The main purpose of the program is to use the open-source database to develop novel, effective, and less toxic therapies. We downloaded TARGET-OS RNA-Sequencing data through R studio and merged the mRNA expression of genes with clinical information (vital status, survival time and gender). Further, we analyzed differential gene expressions between dead and alive patients based on TARGET-OS project. By this study, we found 5758 differentially expressed genes between deceased and alive patients with a false discovery rate below 0.05; 4469 genes were upregulated in deceased patients compared to alive, whereas 1289 genes were downregulated. The survival-related genes were obtained using Kaplan-Meier survival analysis and Cox univariate regression (KM < 0.05 and Cox
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.